Tarsus Pharmaceuticals price to free cash flow TARS
Market value divided by free cash flow over the last twelve months, since 2021.
- Today, Nov 2, 2026
- 57.5×
- 5-year median
- 70.8×
- Against its 5-year history
- 23rd
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 50.8× to 120×
- Peer median
- 30.2×
Tarsus Pharmaceuticals' price to free cash flow is 57.5× as of Nov 2, 2026.
That is below its 5-year median of 70.8×, lower than on 77% of days in the last 5 years.
Over that time it ranged from 50.8× in Aug 2026 to 120× in Apr 2022.
The median for 10 biotech stocks of a similar size is 30.2×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 57.5× | 50.8× | 71.1× |
| 2025 | n/m a value too high to mean anything | ||
| 2024 | n/m a value too high to mean anything | ||
| 2023 | n/m a value too high to mean anything | ||
| 2022 | 72.6× | 53.6× | 120× |
| 2021 | 83.2× | 83.2× | 101× |
Against its peers
Companies in Biotechnology nearest Tarsus Pharmaceuticals' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| TARSTarsus Pharmaceuticals | 57.5× |
| ADMAAdma Biologics | 21.3× |
| VCELVericel | 33.6× |
| KRYSKrystal Biotech | 34.0× |
| RGENRepligen | 87.2× |
| TECHBIO-TECHNE | 43.3× |
| MGTXMeiraGTx | 85.5× |
| HALOHalozyme Therapeutics | 18.2× |
| NBIXNeurocrine Biosciences | 17.0× |
| EXELExelixis | 14.8× |
| ALNYAlnylam Pharmaceuticals | 26.7× |
| Peer median | 30.2× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Tarsus Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.